Taysha Gene Therapies, Inc. (TSHA) shares outstanding
Taysha Gene Therapies, Inc. (TSHA) had 319.71M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 27.8% higher than the 250.13M of fiscal 2024. Figures as of 18 Nov 2026, 11:47 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Shares outstanding, fiscal 2025
- 319.71M
- Change on fiscal 2024
- +27.8%
- Highest on record
- 319.71Mfiscal 2025
- Lowest on record
- 37.65Mfiscal 2021
- Fiscal years on record
- 52021–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Taysha Gene Therapies, Inc. shares outstanding, in more detail
The market data feed counts 326.05M shares outstanding today.
Across the 5 fiscal years on record (2021–2025), the highest was 319.71M in fiscal 2025 and the lowest 37.65M in fiscal 2021.
Shares outstanding by fiscal year
Taysha Gene Therapies, Inc. shares outstanding, year by year
| Fiscal year | Shares outstanding | Change | Year ended |
|---|---|---|---|
| 2025 | 319.71M | 27.8% up | |
| 2024 | 250.13M | 115.4% up | |
| 2023 | 116.12M | 164.2% up | |
| 2022 | 43.95M | 16.7% up | |
| 2021 | 37.65M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.
How to read it
A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.
Taysha Gene Therapies, Inc., figure by figure
- Taysha Gene Therapies, Inc. market cap
- Taysha Gene Therapies, Inc. revenue
- Taysha Gene Therapies, Inc. earnings
- Taysha Gene Therapies, Inc. earnings per share (EPS)
- Taysha Gene Therapies, Inc. P/E ratio
- Taysha Gene Therapies, Inc. P/S ratio
- Taysha Gene Therapies, Inc. P/B ratio
- Taysha Gene Therapies, Inc. free cash flow
- Taysha Gene Therapies, Inc. operating margin
- Taysha Gene Therapies, Inc. dividend
- Taysha Gene Therapies, Inc. total debt
- Taysha Gene Therapies, Inc. cash on hand
- Taysha Gene Therapies, Inc. total assets
- Taysha Gene Therapies, Inc. return on equity (ROE)
- Taysha Gene Therapies, Inc. return on invested capital (ROIC)
Taysha Gene Therapies, Inc. (TSHA) overview: price, valuation and scorecard
Taysha Gene Therapies, Inc. shares outstanding: questions and answers
How many shares does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. (TSHA) had 319.71M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 27.8% higher than the 250.13M of fiscal 2024. The market data feed counts 326.05M shares outstanding today.
What are the highest and lowest diluted share count figures on record for Taysha Gene Therapies, Inc.?
Across the 5 fiscal years on record (2021–2025), the highest was 319.71M in fiscal 2025 and the lowest 37.65M in fiscal 2021.
How is Taysha Gene Therapies, Inc.'s diluted share count calculated?
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For Taysha Gene Therapies, Inc. it is on record here for 5 fiscal years, 2021 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: shares outstanding
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Taysha Gene Therapies, Inc. (TSHA) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/TSHA/shares-outstanding
Underlying data: the company's filings with the SEC and Yahoo Finance.